NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeOnc Technologies Holdings (NASDAQ: NTHI) reported additional insider buying as it prepares for FDA discussions on its investigational brain cancer therapy NEO100.
CEO Amir Heshmatpour purchased 80,000 shares, bringing his direct holdings to 3,333,000 shares; Chief Medical Officer Thomas Chen bought 5,016 shares. An FDA meeting scheduled for early January 2027 will address a potential accelerated approval pathway and proposed Phase 3 study. Two November 13 presentations will cover updated NEO100 results and NEO212 Phase 1 findings.
Previously announced NEO100 Phase 2a results showed six-month progression-free survival—patients alive without disease worsening—of 48.9% versus a 20% historical benchmark. Median overall survival was 26.09 months, with no major toxicities reported. An October memorandum with the Department of Health – Abu Dhabi outlines potential research collaboration.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointNEO100 six-month progression-free survival reached 48.9% versus a prespecified 20% historical benchmark; reported p-value was 0.0047.
- Moderate pointFDA granted an early January 2027 meeting to discuss NEO100 development and potential accelerated approval.
- Moderate point. Forward-looking: it has not happened yet and may not happen.NeOnc plans a randomized Phase 3 study comparing NEO100 with investigator-selected standard-of-care chemotherapy.
- Minor pointCEO purchases of 80,000 shares increased his directly held position to 3,333,000 shares.
- Minor pointChief Medical Officer purchases totaled 5,016 shares, approximately $20,000, through his IRA.
3 minor points
- Minor pointNEO100 median overall survival was 26.09 months; 86.7% of patients were alive at six months.
- Minor pointNEO100 cohort had no major toxicities reported, with adverse events predominantly low-grade.
- Minor point. Forward-looking: it has not happened yet and may not happen.NeOnc plans to explore research, training and potential trial opportunities with the Department of Health – Abu Dhabi.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed approval strategy requires a confirmatory Phase 3 trial underway with enrollment ongoing at application.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential accelerated approval and the proposed Phase 3 design remain subject to FDA discussion.
- Minor pointAbu Dhabi collaboration remains a memorandum of understanding, with regional operations and manufacturing activities only exploratory.
- Minor pointShort interest grew to over 920,000 shares for the October 30 reporting period.
Key Figures
- CEO shares purchased
- 80,000 shares
- Open-market purchases reported in the latest filings
- CEO purchase value
- Approximately $333,100
- Additional open-market purchases
- 2026 CEO purchases
- Approximately 341,000 shares
- Updated 2026 total stated in the article
- FDA Type B meeting
- Early January 2027
- Scheduled discussion of NEO100 pathway and proposed Phase 3 design
- Six-month progression-free survival
- 48.9% vs. 20%
- NEO100 Phase 2a result vs. prespecified historical benchmark
- P-value
- 0.0047
- NEO100 Phase 2a result
- Median overall survival
- 26.09 months
- NEO100 Phase 2a result
- Alive at six months
- 86.7%
- NEO100 Phase 2a result
Historical Context
-
Earlier report documented 80,000 CEO shares purchased, preceding the additional insider-buying filings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
type b end-of-phase meeting regulatory
505(b)(2) new drug application regulatory
accelerated approval regulatory
pharmacokinetics medical
p-value technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New insider filings show continued open-market buying by CEO Amir Heshmatpour, while the company prepares to discuss a potential accelerated approval strategy and Phase 3 trial design with regulators
DENVER, Nov. 12, 2026 (GLOBE NEWSWIRE) -- (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading into a potentially important period for its clinical programs, with additional insider purchases coinciding with a newly announced FDA meeting that could help determine the development pathway for its investigational brain cancer therapy, NEO100.
Two Form 4 filings dated November 12 add important detail to the company's recent insider-buying activity. CEO Amir F. Heshmatpour reported purchasing 80,000 shares across November 19-11, including 50,000 shares at a weighted average price of
The latest filing follows a series of purchases throughout 2026, with the updated total 2026 purchases hitting approximately 341,000 shares.
The latest filings also show buying by another senior insider. Thomas C. Chen, the company's Chief Medical Officer, reported purchasing 2,732 shares on November 9 at
FDA meeting moves NEO100 toward a more defined regulatory discussion
The most significant recent development may be NeOnc's November 11 announcement that the FDA granted a Type B End-of-Phase meeting, scheduled for early January 2027, to discuss a potential accelerated approval pathway for intranasal NEO100.
This is more consequential than a routine regulatory update because the company intends to ask the FDA whether its existing clinical and nonclinical package could support a 505(b)(2) New Drug Application seeking accelerated approval under Section 506(c) of the Federal Food, Drug, and Cosmetic Act.
NeOnc also plans to seek agreement on the design of NEO100-012, a proposed multicenter, randomized, controlled Phase 3 study. The company describes the proposed trial as a comparison of intranasal NEO100 against investigator's-choice standard-of-care chemotherapy in patients with recurrent or progressive IDH-mutant grade 4 astrocytoma. Overall survival would serve as the primary endpoint.
Under the company's proposed strategy, a confirmatory Phase 3 trial would be underway, with enrollment ongoing, at the time of any accelerated-approval application. Its final overall survival analysis would then be intended to verify clinical benefit and support conversion to traditional approval.
NeOnc also intends to discuss the adequacy of its nonclinical safety package, the scientific bridge between published perillyl alcohol research and its intranasal formulation, and potential eligibility for Breakthrough Therapy designation.
These are important questions because regulatory feedback could influence the size, design, timing and cost of the next clinical-development stage.
The company has said it expects to provide an update after receiving and reviewing the FDA's official meeting minutes.
November 13 presentations could provide additional clinical detail
Another near-term catalyst is the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), taking place November 12–15 in Philadelphia. NeOnc has announced two poster presentations scheduled for Friday, November 13, from 7:30 to 9:30 p.m. Eastern.
The first presentation, abstract CTNI-26, is titled "Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma: Updated Results from a Phase 1/2a Study and Compassionate Use Experience."
Presented by Thomas C. Chen, MD, PhD, the poster is particularly relevant because it is intended to provide updated results combining the Phase 1/2a experience with compassionate-use observations. Investors and clinicians will be looking for additional information about the duration of responses, survival outcomes, patient characteristics and the consistency of the reported clinical experience.
The second presentation, abstract CTNI-27, is titled "Oral NEO212 in TMZ-Resistant Recurrent GBM and Brain Metastases: Phase 1 Safety, PK, and Early Signals of Activity."
Presented by Josh Neman, PhD, the poster will address Phase 1 safety, pharmacokinetics and early signals of activity for NEO212, an investigational oral conjugate of temozolomide and perillyl alcohol.
This presentation matters because NEO212 represents a separate development opportunity from NEO100. While NEO100 is being evaluated as an intranasal therapy, NEO212 is designed as an oral approach for central nervous system cancers, including recurrent glioblastoma.
The clinical case: promising Phase 2a results
The regulatory discussion follows NeOnc's August 12 announcement of topline Phase 2a results for NEO100 in recurrent or progressive IDH1-mutant high-grade glioma.
NeOnc reported that the study achieved six-month progression-free survival of
The company reported no major toxicities across the cohort, with adverse events predominantly low-grade.
These results are relevant because recurrent IDH-mutant high-grade glioma remains a serious treatment challenge, and the company is seeking to develop an approach that delivers therapy intranasally rather than relying exclusively on conventional systemic administration.
NEO100 is a highly purified form of perillyl alcohol. Its intranasal delivery approach is designed to provide a non-invasive route to the brain.
Analyst coverage provides a key dimension to the investment picture
BTIG reiterated its Buy rating and maintained the
BTIG is not alone in maintaining a positive view of NeOnc. Roth MKM analyst Jonathan Aschoff carries a Buy rating and
The short-interest angle adds another dimension
NTHI has also attracted attention from market participants tracking short interest.
The October 30 reporting period shows that the short interest has grown toto over 920,000 shares and over 7 days to cover, and it remains over 5 days to cover based on the corresponding average trading volume.
The company's relatively limited reported float compared with total shares outstanding is also relevant to potential volatility.
Abu Dhabi collaboration adds an international dimension
NeOnc has also announced a memorandum of understanding with the Department of Health – Abu Dhabi, signed in October 2026.
The proposed collaboration covers scientific exchange, specialist training, real-world evidence and an assessment of potential clinical trial opportunities in the emirate. The parties also intend to explore the possibility of a regional presence and future manufacturing, supply or distribution activities.
The company previously disclosed that two children in Abu Dhabi were receiving investigational NEO100 through its Compassionate Care program, with a third expected at the time of the announcement.
The agreement could create opportunities to expand clinical research and institutional relationships, particularly in pediatric oncology.
What investors should watch next
The coming weeks and months provide several identifiable milestones:
- November 13, 2026: Updated NEO100 Phase 1/2a and compassionate-use data, alongside NEO212 Phase 1 safety, pharmacokinetic and early activity findings, at the SNO Annual Meeting.
- Early January 2027: FDA Type B End-of-Phase meeting covering the potential accelerated approval pathway, proposed Phase 3 design, nonclinical safety package, scientific bridging and possible Breakthrough Therapy designation.
- Following the FDA meeting: Publication and review of official FDA meeting minutes, which should provide greater clarity on regulatory feedback and the proposed clinical-development strategy.
- Subsequent development: Progress toward the proposed NEO100-012 randomized Phase 3 trial, including final protocol requirements, funding, site activation and enrollment plans.
About 247MarketNews
In today's fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
247MarketNews
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.